がん診断薬市場：診断タイプ、適応症、成分、エンドユース別-2023-2030年の世界予測

がん診断薬の世界市場は、2023年に299億5,000万米ドル、CAGR 11.60%で大きく成長し、2030年には650億6,000万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のがん診断薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.がん診断薬の世界市場規模および予測は？

2.予測期間中、世界のがん診断薬市場を形成するCOVID-19の阻害要因と影響は？

3.がん診断薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.がん診断薬の世界市場における競争戦略は？

5.がん診断薬の世界市場における技術動向と規制の枠組みは？

6.がん診断薬の世界市場における主要ベンダーの市場シェアは？

7.がん診断薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 若年層や高齢者の間でがんの負担が増大
    • がん啓発のための政府の取り組みとキャンペーンの強化
    • がん診断に対する有利な償還枠組み
  • 抑制要因
    • それに伴うがん診断機器の高額化と腫瘍専門医の不足
  • 機会
    • がんのスクリーニング、検出、診断のための革新的なツールの導入
    • がん診断におけるナノテクノロジーとナノマテリアルの統合
  • 課題
    • がん診断薬の不適切な結果と誤った結果
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 がん診断薬市場診断タイプ別

• 生検
• 血液化学検査
  • 全血球計算（CBC）
  • 細胞遺伝学的分析
  • 免疫表現型検査
  • リキッドバイオプシー
  • 喀痰細胞診
  • 腫瘍マーカー検査
  • 尿細胞学
• 画像検査
  • 骨スキャン
  • CTスキャン
  • 磁気共鳴画像法（MRI）
  • 核スキャン
  • 陽電子放射断層撮影法（PET）スキャン
  • 超音波
  • X線

第7章 がん診断薬市場適応症別

• 膀胱がん
• 血液がん
• 乳がん
• 結腸直腸がん
• 腎臓がん
• 肝臓がん
• 肺がん
• 膵臓がん
• 前立腺がん
• 皮膚ガン

第8章 がん診断薬市場：コンポーネント別

• 消耗品
• 楽器
• ソフトウェア

第9章 がん診断薬市場：最終用途別

• 診断研究所
• 病院
• 研究センター

第10章 南北アメリカのがん診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のがん診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのがん診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別
  • 合併・買収
  • 契約、コラボレーション、パートナーシップ
  • 新製品発売と機能強化
  • 投資、資金調達
  • 受賞・表彰・拡大

第14章 掲載企業一覧

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2022 VS 2030 (%)
• FIGURE 5. CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
• FIGURE 6. CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2022 VS 2030 (%)
• FIGURE 7. CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2022 VS 2030 (%)
• FIGURE 8. CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. CANCER DIAGNOSTICS MARKET DYNAMICS
• FIGURE 10. CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 5. CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 7. CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. CANCER DIAGNOSTICS MARKET SIZE, BY COMPLETE BLOOD COUNT (CBC), BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CANCER DIAGNOSTICS MARKET SIZE, BY CYTOGENETIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. CANCER DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. CANCER DIAGNOSTICS MARKET SIZE, BY SPUTUM CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR MARKER TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. CANCER DIAGNOSTICS MARKET SIZE, BY URINE CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 16. CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. CANCER DIAGNOSTICS MARKET SIZE, BY BONE SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. CANCER DIAGNOSTICS MARKET SIZE, BY CT-SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. CANCER DIAGNOSTICS MARKET SIZE, BY NUCLEAR SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. CANCER DIAGNOSTICS MARKET SIZE, BY X-RAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 36. CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 40. CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 62. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 63. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 64. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 65. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 67. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 95. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 96. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 97. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 99. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 100. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 101. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 102. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 103. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 105. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 107. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 113. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 114. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 118. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 119. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 120. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 121. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 125. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 126. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 127. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 130. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 132. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 133. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 135. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 136. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 138. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 139. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 141. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 142. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 143. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 144. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 145. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 147. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 148. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 149. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 150. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 151. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 153. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 154. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 155. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 156. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 157. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 159. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 167. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 168. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 169. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 170. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 172. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 173. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 174. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 175. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 176. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 178. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 179. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 180. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 181. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 182. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 184. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 185. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 186. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 187. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 188. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 190. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 191. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 192. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 193. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 194. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 195. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 196. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 197. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 198. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 199. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 200. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 201. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 202. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 203. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 204. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 205. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 206. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 207. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 208. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 209. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 210. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 211. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 212. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 213. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 214. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 215. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 216. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 217. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 218. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 219. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 220. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 221. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 222. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 223. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 224. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 225. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 226. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 227. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 228. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 229. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 230. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 231. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 232. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 233. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 234. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 235. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 236. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 237. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 238. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 239. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 240. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 241. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 242. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 243. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 244. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 245. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 246. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 247. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 248. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 249. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 250. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 251. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 252. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 253. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 254. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 255. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 256. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 257. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 258. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 259. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 260. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 261. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 262. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 263. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 264. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 265. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 266. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 267. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 268. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 269. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 270. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 271. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 272. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 273. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 274. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 275. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 276. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 277. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 278. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 279. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 280. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 281. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 282. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 283. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 284. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 285. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 286. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 287. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 288. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 289. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 290. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 291. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 292. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 293. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 294. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 295. CANCER DIAGNOSTICS MARKET LICENSE & PRICING

The Global Cancer Diagnostics Market is forecasted to grow significantly, with a projected USD 29.95 billion in 2023 at a CAGR of 11.60% and expected to reach a staggering USD 65.06 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Diagnostics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Diagnostics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Diagnostic Type, market is studied across Biopsy, Blood Chemistry Tests, and Imaging Tests. The Blood Chemistry Tests is further studied across Complete Blood Count (CBC), Cytogenetic Analysis, Immunophenotyping, Liquid Biopsy, Sputum Cytology, Tumor Marker Tests, and Urine Cytology. The Imaging Tests is further studied across Bone Scan, CT-Scan, Magnetic Resonance Imaging (MRI), Nuclear Scan, Positron Emission Tomography (PET) Scan, Ultrasound, and X-Rays. The Imaging Tests commanded largest market share of 37.76% in 2022, followed by Biopsy.

Based on Indication, market is studied across Bladder Cancer, Blood Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer. The Lung Cancer commanded largest market share of 19.99% in 2022, followed by Breast Cancer.

Based on Components, market is studied across Consumables, Instruments, and Software. The Instruments commanded largest market share of 74.75% in 2022, followed by Consumables.

Based on End-Use, market is studied across Diagnostic Laboratories, Hospitals, and Research Centers. The Hospitals commanded largest market share of 52.45% in 2022, followed by Diagnostic Laboratories.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 38.45% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Diagnostics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Diagnostics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Diagnostics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Diagnostics Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Diagnostics Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Diagnostics Market?

6. What is the market share of the leading vendors in the Global Cancer Diagnostics Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Cancer Diagnostics Market, by Diagnostic Type, 2022 vs 2030
• 4.3. Cancer Diagnostics Market, by Indication, 2022 vs 2030
• 4.4. Cancer Diagnostics Market, by Components, 2022 vs 2030
• 4.5. Cancer Diagnostics Market, by End-Use, 2022 vs 2030
• 4.6. Cancer Diagnostics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing burden of cancer among younger and geriatric population
    • 5.1.1.2. Rising government initiatives and campaigns for cancer awareness
    • 5.1.1.3. Favorable reimbursement framework for cancer diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. Associated high cost of cancer diagnostic equipment and lack of oncologists
  • 5.1.3. Opportunities
    • 5.1.3.1. Deployement of innovative tools for cancer screening, detection, and diagnostics
    • 5.1.3.2. Integration of nanotechnology and nanomaterials in cancer diagnosis
  • 5.1.4. Challenges
    • 5.1.4.1. Inadequate and false results of cancer diagnostics
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Cancer Diagnostics Market, by Diagnostic Type

• 6.1. Introduction
• 6.2. Biopsy
• 6.3. Blood Chemistry Tests
  • 6.3.1. Complete Blood Count (CBC)
  • 6.3.2. Cytogenetic Analysis
  • 6.3.3. Immunophenotyping
  • 6.3.4. Liquid Biopsy
  • 6.3.5. Sputum Cytology
  • 6.3.6. Tumor Marker Tests
  • 6.3.7. Urine Cytology
• 6.4. Imaging Tests
  • 6.4.1. Bone Scan
  • 6.4.2. CT-Scan
  • 6.4.3. Magnetic Resonance Imaging (MRI)
  • 6.4.4. Nuclear Scan
  • 6.4.5. Positron Emission Tomography (PET) Scan
  • 6.4.6. Ultrasound
  • 6.4.7. X-Rays

7. Cancer Diagnostics Market, by Indication

• 7.1. Introduction
• 7.2. Bladder Cancer
• 7.3. Blood Cancer
• 7.4. Breast Cancer
• 7.5. Colorectal Cancer
• 7.6. Kidney Cancer
• 7.7. Liver Cancer
• 7.8. Lung Cancer
• 7.9. Pancreatic Cancer
• 7.10. Prostate Cancer
• 7.11. Skin Cancer

8. Cancer Diagnostics Market, by Components

• 8.1. Introduction
• 8.2. Consumables
• 8.3. Instruments
• 8.4. Software

9. Cancer Diagnostics Market, by End-Use

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Hospitals
• 9.4. Research Centers

10. Americas Cancer Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cancer Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player
  • 13.3.1. Merger & Acquisition
    • 13.3.1.1. Biocare Medical Acquires Empire Genomics
    • 13.3.1.2. Thermo Fisher ties up $2.6B deal for The Binding Site
    • 13.3.1.3. BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
    • 13.3.1.4. Becton Dickinson Acquires Spanish Clinical Flow Cytometry Firm Cytognos
    • 13.3.1.5. Cancer Diagnostics, Inc. Acquires Anatech, Ltd.
  • 13.3.2. Agreement, Collaboration, & Partnership
    • 13.3.2.1. Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection
    • 13.3.2.2. Microsoft Strikes Partnership with Paige To Advance Cancer Diagnostics and Treatment
    • 13.3.2.3. Fujifilm India partners with Soorya Diagnostics LLP to launch CT Scan in Tirur
    • 13.3.2.4. EarlySign Announces Strategic Agreement to Commercialize AI Solution for Early Detection of Cancer
  • 13.3.3. New Product Launch & Enhancement
    • 13.3.3.1. Ibex Medical launches Galen 3.0 cancer diagnostics platform
    • 13.3.3.2. Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
  • 13.3.4. Investment & Funding
    • 13.3.4.1. New Funding to underpin development of Early Stage Cancer Platform Labmate Online
    • 13.3.4.2. Cancer diagnostics company GenoME Diagnostics bags £1.4M funding
    • 13.3.4.3. Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers
  • 13.3.5. Award, Recognition, & Expansion
    • 13.3.5.1. Ibex's Galen Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR
    • 13.3.5.2. Karkinos Healthcare launches 'Advanced Centre For Cancer Diagnostics and Research'

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing